Skip to content
August 15, 2022

Equity.Guru

Investment information for the new generation

Mind Medicine

Some positive action on psychedelic stocks in the last few days. As a technical analyst, there are good signs indicating a reversal is occurring. The downtrend is over, and…
Not So Generalized Disorder “Anxiety is a part of normal life.” Or so I was told. Whether I was simply leaving my apartment to get food or speaking during…
We’re living in interesting times and I mean that in the Chinese curse kind of way. We can’t seem to stop to catch our breath when it comes to…
$901.372M Market Capitalization Mind Medicine Inc. (MNMD.Q) today announced the initiation of a Phase 2a proof-of-concept (POC) trial of lysergic acid diethylamide (LSD) in adult patients with attention deficit…
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
Mind Medicine (MNMD.Q, MMED.NE) announced that they have agreed to partner with Forian (FORA.Q), who provide evidence-based support for clinical and commercial decision making. Forian and MindMed will collaborate…
Mind Medicine (MNMD.Q) announced the addition of Dr. Peter Bergethon to their Scientific Advisory Board. Bergethon is a “world-leading” expert in neurology, digital medicine, and central nervous system (CNS)…
Mind Medicine (MMED.NE, MNMD.Q) announced that J.R. Rahn is stepping down from his roles as CEO and director. Rahn was a co-founder of the company and was at the…
Mind Medicine (MMED.NE) announced the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from a pooled secondary analysis of four Phase I…
Mind Medicine (MMED.E) announced today their intended acquisition of digital medicine and therapeutics start-up, Healthmode, according to a press release. The acquisition brings access to HealthMode’s intellectual property, as…